Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Institutional business has won final FDA approval for its abbreviated new drug application (ANDA) for preservative-free Thiamine Hydrochloride Injection, 100mg/ml, packaged in 200mg/2ml multiple-dose vials.
Subscribe to our email newsletter
Mylan is shipping the product, which is indicated for the treatment of thiamine deficiency, presented in 25-vial packs.
According to IMS Health, Thiamine Hydrochloride Injection, 100mg/ml, had US sales of approximately $18.6m for the 12 months ending 31 March 2012.
At present, Mylan has 169 ANDAs pending FDA approval representing $83.9bn in annual sales.
Thirty-seven of the pending ANDAs are potential first-to-file opportunities, representing $25.6bn in annual brand sales, for the 12 months ending 31 December 2011, according to IMS Health.